Similar Articles |
|
The Motley Fool March 29, 2007 Michael P. Cecil |
Stents on Trial New study results could affect stent sales -- at least in the short term. |
BusinessWeek July 18, 2005 John Carey |
Is Heart Surgery Worth It? Physicians are questioning whether bypasses and angioplasties necessarily prolong patients' lives. |
BusinessWeek October 9, 2006 John Carey |
"No One Wanted To Hear" Renu Virmani warned that, over time, some drug-coated stents could lead to fatal clots. |
BusinessWeek August 8, 2005 Amy Barrett |
BW 50: In A Bind Over Stents Safety concerns about drug-coated stents from Johnson & Johnson and Boston Scientific could open the way for rivals. |
The Motley Fool December 13, 2006 Stephen Albainy-Jenei |
The Latest Standpoint on Stents A panel of experts reaches mixed conclusions on the safety and effectiveness of drug-coated stents. Investors, take note. |
The Motley Fool October 31, 2006 Michael P. Cecil |
An Opening for Plavix New data suggesting problems with drug-eluting stents may translate into more sales of the blood thinner Plavix and fewer sales of the stents. Investors, take note. |
BusinessWeek September 9, 2010 Michelle Cortez |
Coming Soon: Dissolvable Stents New stents from Abbott Labs and others appear to reduce the risk of blood clots |
BusinessWeek October 29, 2007 Arlene Weintraub |
Medtronic's Uncertain Endeavor The drug-coated stent might have made up for Medtronic's recent product recall, but renewed scrutiny of the device has executives scaling back expectations |
BusinessWeek June 9, 2009 John Carey |
Giving Patients the Data They Need A growing effort by doctors, insurers, and politicians helps people make better-informed medical decisions |
The Motley Fool September 25, 2008 Brian Orelli |
Uh-Oh, Stent Makers Drugs are just as good as stents. |
The Motley Fool October 25, 2007 Brian Orelli |
Time to Invest in Stents? Stent devices have seen slumping sales over the last few years. Is it time now to invest in the companies that produce them? |
Managed Care February 2007 Maggie Mahar |
Why Market Competition Will Not Mend Our Health Care System Doctors have a saying: 'Half of what we know is wrong.' In which half is the conventional wisdom that competition is society's best hope for improving quality and controlling costs? |
The Motley Fool September 17, 2007 Brian Orelli |
Can't See the Trees for the Forest Meta-analysis finds J&J's drug-coated stents are safer than Boston Scientific's stents, maybe. Can J&J use the complex study results to help their falling stent sales? |
Managed Care June 2006 Tom Pope |
Hard to Curb Overuse of Drug-Eluting Stents Health plans find themselves paying for the latest and greatest stent without any control over usage. Even bare-metal stents may be overused. |
Managed Care July 2003 Thomas Morrow |
Drug-Eluting Stents To Transform Cardiovascular Medicine By reducing restenosis, these devices will save managed care money. |
The Motley Fool June 1, 2005 Stephen D. Simpson |
Stent Wars: Revenge of the Bypass A new study supports a long-held belief that bypass surgery is better than using stents. What does it mean for stent makers and investors? |
BusinessWeek April 17, 2006 Amy Barrett |
Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created. |
BusinessWeek October 9, 2006 |
Boston Scientific's Double Bypass First, quality problems with its defibrillators. Now, doubts about the safety of Boston Scientific's coated stents |
BusinessWeek June 20, 2005 Spencer E. Ante |
Powering Through Clogged Arteries FoxHollow's SilverHawk is a promising alternative to stents and bypass surgery. |
Health July 2007 Curt Pesmen |
Surgery to Avoid #3: Angioplasty A new study has found that heart medication is just as effective as this invasive surgery. |
The Motley Fool March 22, 2004 Seth Jayson |
Stent Wars Going Strong New studies show stents do little to stop heart attacks. What does that mean for stent makers? |
Fast Company February 1, 2008 Amy Feldman |
Artery, Heal Thyself Abbott's new absorbable stent could change heart surgery and revive a $5 billion business. |
Chemistry World November 7, 2011 Kate McAlpine |
Spotting Artery Damage Before a Heart Attack An international team of medical researchers has developed a way to perform a check up on an artery's physical structure and molecular markers of ill health by coupling a catheter with imaging technology. |
BusinessWeek October 29, 2007 Arlene Weintraub |
When Good Buzz Goes Bad How Xtent is weathering safety worries about medicated stents. |
The Motley Fool December 13, 2006 Matthew Crews |
Less Support for Drug-Eluting Stents? The FDA responds to a recent controversy. The regulator's stance represents a good-faith-take on the newer stents, which is good news for drug companies. |
The Motley Fool March 8, 2005 Stephen D. Simpson |
The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents. |
The Motley Fool July 19, 2005 Stephen D. Simpson |
Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note. |
The Motley Fool May 28, 2009 Brian Orelli |
Boston Scientific Back in an Atomic Way Can its tiny stent save the day? |
The Motley Fool August 29, 2008 Brian Orelli |
Stent Makers Getting Desperate Johnson & Johnson, the first company to bring a drug-eluting stent to the U.S. market, seems like it might be getting a little desperate, as competition increases. |
BusinessWeek September 22, 2003 Faith Arner |
When Will This Stent See Circulation? Boston Scientific must clear the FDA, among other hurdles. |
BusinessWeek October 31, 2005 Spencer E. Ante |
Crashing The Stent Party Conor Medsystems is trying to take on Goliaths J&J and Boston Scientific. |
The Motley Fool June 30, 2011 Brian Orelli |
Medical-Device Makers' Killer: Health-Care Inflation High prices have painted their targets. |
The Motley Fool March 31, 2010 Brian Orelli |
How Do You Put a Price on Pain? Price controls could wreck havoc on expensive therapies that control pain. |
The Motley Fool December 6, 2007 Brian Orelli |
An Unlikely Chat With Your Doctor J&J starts direct-to-consumer advertising of its drug-eluting stent. Can it really pay off? |
The Motley Fool May 27, 2010 Brian Orelli |
Ever-Evolving Stent Technology (and How to Profit From It) Stay ahead of the curve. |
The Motley Fool February 1, 2005 Stephen D. Simpson |
Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth. |
American Family Physician December 15, 2001 Julia Tucker De Sanctis |
Percutaneous Interventions for Lower Extremity Peripheral Vascular Disease Peripheral vascular disease is a common condition with variable morbidity affecting mostly men and women older than 50 years. More than 70 percent of patients diagnosed with the disease remain stable or improve with conservative management... |
The Motley Fool August 6, 2004 Jeff Hwang |
Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share? |
The Motley Fool May 14, 2008 Brian Orelli |
Abbott Knocks Down Boston Scientific Abbott Labs proves its drug-eluting device works better than its competitors as it presented more data from its ongoing Spirit III trial. |
The Motley Fool February 5, 2008 Brian Orelli |
Medtronic Endeavors to Compete The U.S. drug-eluting stent market just got a little more crowded, after Medtronic announces that the FDA had approved its Endeavor stent for marketing in the U.S. |
The Motley Fool October 20, 2009 Robert Steyer |
The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it. |
The Motley Fool January 12, 2007 Billy Fisher |
Big Week at Boston Scientific The company's off to a great start so far for 2007. Investors, take note. |
The Motley Fool April 8, 2005 Stephen D. Simpson |
Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse? |
The Motley Fool October 8, 2007 Billy Fisher |
Vital Signs at Medtronic The FDA raises question about Medtronic's Endeavor stent. Investors, remember that the company also has a well-diversified product portfolio to protect itself against any unforeseen pitfalls ahead. |
The Motley Fool April 24, 2007 Ryan Fuhrmann |
Boston Scientific Regains Consciousness Recent Boston Scientific results show glimmers of hope. At current prices, the risk/reward tradeoff appears favorable enough to warrant a full checkup on the stock. |
The Motley Fool November 2, 2006 Brian Lawler |
Angiotech's Study Troubles The results of recent studies in medical journals have brought the company's forecasts down. Investors, take note. |
The Motley Fool February 2, 2004 Alyce Lomax |
Boston Scientific's Stent Hopes Nice quarter, but all eyes should be on the Taxus stent. |
The Motley Fool November 17, 2006 Brian Lawler |
Johnson & Johnson's Good Deal If Conor's stent design can alleviate some of the perceived safety worries about stents, then sales from the Cordis division should spring back up, again making it drive revenue growth for Johnson & Johnson, as it did before this year. Investors, take note. |
The Motley Fool April 19, 2005 Stephen D. Simpson |
Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good. |
Chemistry World November 25, 2010 Hayley Birch |
Designing safer stents for heart patients A study by UK researchers provides insights into how the body reacts to the metal stents used to wedge open blocked blood vessels in heart patients. |